AHB-137

Phase 3Small molecule

AAusper Biopharma Co., Ltd.

AHB-137 is one of 53 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Hepatitis BActive, not recruiting

Chronic HepatitisPhase 3

Active, not recruiting

Hepatitis BPhase 2

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Sovaldi

Gilead

Preclinical

34 3

AHB-137

AAusper Biopharma Co., Ltd.

Phase 3

8 4

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 5

Incivek

Vertex Pharmaceuticals

Preclinical

10 6

Intron a

Sanofi

Preclinical

7 7

Roferon-a

Roche

Preclinical

3 8

Medrol

Pfizer

Preclinical

1 9

Dasabuvir

AbbVie

Preclinical

7 10

SOF/VEL

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Chronic Hepatitis

NCT06993480

Q2 2027

Phase 2Active, not recruiting

Hepatitis B

NCT07069569

Phase 2Not yet recruiting

Chronic Hepatitis

NCT07137910

Q3 2027

Phase 3Active, not recruiting

Chronic Hepatitis

NCT07246889

Q4 2028

Phase 2Not yet recruiting

Chronic Hepatitis

NCT07370207

Clinical

Trials by Indication[1]

Chronic Hepatitis8 trials

Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region

Not yet recruiting·AAusperBio Therapeutics Inc.·Phase 2·NCT07370207·84 enrolled

Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).

Active, not recruiting·AAusper Biopharma Co., Ltd.·Phase 2·NCT06550128·86 enrolled

A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

Not yet recruiting·AAusper Biopharma Co., Ltd.·Phase 2·NCT07137910·60 enrolled

Show 5 more trials

A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

Recruiting·AAusper Biopharma Co., Ltd.·Phase 2·NCT06993480·30 enrolled

Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)

Active, not recruiting·AAusper Biopharma Co., Ltd.·Phase 2·NCT06829329·105 enrolled

A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients

Active, not recruiting·AAusper Biopharma Co., Ltd.·Phase 1/2·NCT06115993·129 enrolled

A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B

Completed·AAusperBio Therapeutics Inc.·Phase 1·NCT05717686·64 enrolled

Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)

Active, not recruiting·AAusper Biopharma Co., Ltd.·Phase 3·NCT07246889·577 enrolled

Hepatitis B1 trial

A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs

Active, not recruiting·AAusper Biopharma Co., Ltd.·Phase 2·NCT07069569·127 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for AHB-137. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AHB-137 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AHB-137. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ausper Biopharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAusper Biopharma Co., Ltd.

AHB-137

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Q4 2028

Trials by Indication[1]

Chronic Hepatitis8 trials

Hepatitis B1 trial

References

Drug Info

Quick Facts

Related News